Publications du CNR en 2016

Bernard, J., Armand-Lefèvre, L., Luce, E., Mniai, A. E., Chau, F., Casalino, E., Andremont, A. and Ruppé, E. (2016). Impact of a short exposure to levofloxacin on faecal densities and relative abundance of total and quinolone-resistant Enterobacteriaceae. Clinical Microbiology and Infection 22, 646.e1-646.e4,
Bernard, C., Aubry, A., Chauffour, A., Brossier, F., Robert, J. and Veziris, N. (2016). In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. J Antimicrob Chemother,
Brossier, F. and Aubry, A. (2016). Résistance de Mycobacterium tuberculosis aux antituberculeux. Feuillets Bio 328, 17–25,
Brossier, F., Guindo, D., Pham, A., Reibel, F., Sougakoff, W., Veziris, N. and Aubry, A. (2016). Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. J Clin Microbiol 54, 1573–1580,
Brossier, F., Cambau, E., Tessier, E., Jarlier, V. and Sougakoff, W. (2016). The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis. Tuberculosis 101, 144–145,
Brossier, F., Boudinet, M., Jarlier, V., Petrella, S. and Sougakoff, W. (2016). Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Tuberculosis 100, 15–24,
Chauffour, A., Robert, J., Veziris, N., Aubry, A. and Jarlier, V. (2016). Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium ulcerans Infection in Mice. PLOS Neglected Tropical Diseases 10, e0005066,
Chazel, M., Marchandin, H., Keck, N., Terru, D., Carrière, C., Ponsoda, M., Jacomo, V., Panteix, G., Bouzinbi, N., Bañuls, A.-L., Choisy, M., Solassol, J., Aubry, A. and Godreuil, S. (2016). Evaluation of the SLOMYCO Sensititre® panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates. Annals of Clinical Microbiology and Antimicrobials 15, 30,
Crabol, Y., Catherinot, E., Veziris, N., Jullien, V. and Lortholary, O. (2016). Rifabutin: where do we stand in 2016? J Antimicrob Chemother dkw024,
Fox, G. J., Benedetti, A., Mitnick, C. D., Pai, M., Menzies, D. and Mdr-Tb, T. C. G. for M.-A. of I. P. D. in (2016). Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLOS ONE 11, e0151724,
Fox, G. J., Mitnick, C. D., Benedetti, A., Chan, E. D., Becerra, M., Chiang, C.-Y., Keshavjee, S., Koh, W.-J., Shiraishi, Y., Viiklepp, P., Yim, J.-J., Pasvol, G., Robert, J., Shim, T. S., Shin, S. S., Menzies, Dick, Mdr-Tb, for the C. G. for M.-A. of I. P. D. in, Ahuja, S., Ashkin, D., Avendaño, M., Banerjee, R., Bauer, M., Burgos, M., Centis, R., Cobelens, F., Cox, H., D’Ambrosio, L., Lange, W. C. M. de, DeRiemer, K., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Gandhi, N., Garcia-Garcia, L., Granich, R. M., Hollm-Delgado, M. G., Holtz, T. H., Hopewell, P., Iseman, M., Jarlsberg, L. G., Kim, H. R., Lancaster, J., Lange, C., Leimane, V., Leung, C. C., Li, J., Menzies, D., Migliori, G. B., Narita, M., Nathanson, E., Odendaal, R., O’Riordan, P., Pai, M., Palmero, D., Park, S. K., Pena, J., Pérez-Guzmán, C., Ponce-de-Leon, A., Quelapio, M. I. D., Quy, H. T., Riekstina, V., Royce, S., Salim, M., Schaaf, H. S., Seung, K. J., Shah, L., Shean, K., Sifuentes-Osornio, J., Sotgiu, G., Strand, M. J., Sung, S. W., Tabarsi, P., Tupasi, T. E., Vargas, M. H., Altena, R. van, Walt, M. van der, Werf, T. S. van der, Westenhouse, J. and Yew, W. W. (2016). Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis 62, 887–895,
Guglielmetti, L., Dû, D. L., Veziris, N., Caumes, E., Marigot-Outtandy, D., Yazdanpanah, Y., Robert, J. and Fréchet-Jachym, M. (2016). Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? European Respiratory Journal 48, 582–585,
Henry, B., Revest, M., Dournon, N., Epelboin, L., Mellon, G., Bellaud, G., Mordant, P., Le Dû, D., Véziris, N., Bernard, C., Morel, S., Jauréguiberry, S., Michelet, C., Bricaire, F., Tattevin, P. and Caumes, É. (2016). Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009–2014. Emerging Infectious Diseases 22, 518–521,
Lachâtre, M., Rioux, C., Dû, D. L., Fréchet-Jachym, M., Veziris, N., Bouvet, E. and Yazdanpanah, Y. (2016). Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 16, 294,
Lafeuille, E., Veziris, N., Sougakoff, W., Roure, F., Le Dû, D., Dournon, N., Caumes, E., Jarlier, V., Aubry, A., Robert, J. and Bernard, C. (2016). XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions. Médecine et Maladies Infectieuses 46, 52–55,
Lange, C., Duarte, R., Fréchet-Jachym, M., Guenther, G., Guglielmetti, L., Olaru, I. D., Oliveira, O., Rumetshofer, R., Veziris, N. and van Leth, F. (2016). Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Am J Respir Crit Care Med 194, 1029–1031,
Lortholary, O., Roussillon, C., Boucherie, C., Padoin, C., Chaix, M.-L., Breton, G., Rami, A., Veziris, N., Patey, O., Caumes, E., May, T., Molina, J.-M., Robert, J., Tod, M., Fagard, C. and Chêne, G. (2016). Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy 71, 783–793,
Mieras, L., Anthony, R., van Brakel, W., Bratschi, M. W., van den Broek, J., Cambau, E., Cavaliero, A., Kasang, C., Perera, G., Reichman, L., Richardus, J. H., Saunderson, P., Steinmann, P. and Yew, W. W. (2016). Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infectious Diseases of Poverty 5, 46,
Mougari, F., Amarsy, R., Veziris, N., Bastian, S., Brossier, F., Berçot, B., Raskine, L. and Cambau, E. (2016). Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother 71, 2208–2212,
Mougari, F., Guglielmetti, L., Raskine, L., Sermet-Gaudelus, I., Veziris, N. and Cambau, E. (2016). Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. Expert Review of Anti-infective Therapy 14, 1139–1154,
Pantel, A., Petrella, S., Veziris, N., Matrat, S., Bouige, A., Ferrand, H., Sougakoff, W., Mayer, C. and Aubry, A. (2016). Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. J Antimicrob Chemother 71, 2428–2431,
Parize, P., Hamelin, A., Veziris, N., Morand, P. C., Guillemain, R., Lortholary, O. and Dupin, N. (2016). Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. Journal of the European Academy of Dermatology and Venereology 30, 101–105,
Raharolahy, O., Ramarozatovo, L. S., Ranaivo, I. M., Sendrasoa, F. A., Andrianarison, M., Andrianarivelo, M. R., Cambau, E. and Rabenja, F. R. (2016). A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. Case Reports in Infectious Diseases 2016, 4632369,

Publications du CNR en 2017

Allerberger, F., Cambau, E. and Lange, C. (2017). Joint efforts urgently needed at times of emerging tuberculosis drug resistance. Clinical Microbiology and Infection 23, 129–130,
Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Mukadi, B. K., Mathys, V., Gagneux, S., Niemann, S., Ingen, J. V. and Cambau, E. (2017). Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection 23, 167–172,
Appelgren, A., Morquin, D., Dufour, S., Le Moing, V., Reynes, J., Lotthé, A., Parer, S., Corbeau, C., Aubry, A., Sougakoff, W., Solassol, J., Bonzon, L., Dumont, Y. and Godreuil, S. (2017). Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016. Journal of Hospital Infection,
Aubry, A., Mougari, F., Reibel, F. and Cambau, E. (2017). Mycobacterium marinum. Microbiology Spectrum 5,
Bouchet, F., Martin, B., Aubry, A., Veziris, N., Lavigne, J.-P. and Sotto, A. (2017). Should single antibiotic therapy be avoided for nontuberculous mycobacteria? Médecine et Maladies Infectieuses,
Brossier, F. and Sougakoff, W. (2017). Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis. Médecine et Maladies Infectieuses 47, 340–348,
Brossier, F., Pham, A., Bernard, C., Aubry, A., Jarlier, V., Veziris, N., Sougakoff, W. and CNR-MyRMA, O. B. of T. (2017). Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother 61, e01299-16,
Delafont, V., Samba-Louaka, A., Cambau, E., Bouchon, D., Moulin, L. and Héchard, Y. (2017). Mycobacterium llatzerense, a waterborne Mycobacterium, that resists phagocytosis by Acanthamoeba castellanii. Scientific Reports 7, 46270,
Fournier, A., Bernard, C., Sougakoff, W., Quelet, S., Antoun, F., Charlois-Ou, C., Dormant, I., Dufour, M.-O., Hocine, N., Jarlier, V. and Veziris, N. (2017). Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission. European Respiratory Journal 50, 1700891,
Guglielmetti, L., Jaspard, M., Dû, D. L., Lachâtre, M., Marigot-Outtandy, D., Bernard, C., Veziris, N., Robert, J., Yazdanpanah, Y., Caumes, E. and Fréchet-Jachym, M. (2017). Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. European Respiratory Journal 49, 1601799,
Guglielmetti, L., Hewison, C., Avaliani, Z., Hughes, J., Kiria, N., Lomtadze, N., Ndjeka, N., Setkina, S., Shabangu, A., Sikhondze, W., Skrahina, A., Veziris, N. and Furin, J. (2017). Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. The International Journal of Tuberculosis and Lung Disease 21, 167–174,
Jaspard, M., Elefant-Amoura, E., Melonio, I., de Montgolfier, I., Veziris, N. and Caumes, E. (2017). Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. Emerging Infect Dis 23,
Leyer, C., Gregorowicz, G., Mougari, F., Raskine, L., Cambau, E. and Briel, D. de (2017). Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media. Journal of Clinical Microbiology 55, 2045–2054,
Maitre, T., Aubry, A. and Veziris, N. (2017). Molecular Drug-Susceptibility Test for Tuberculosis. New England Journal of Medicine 377, 2403–2404,
Maitre, T., Petitjean, G., Chauffour, A., Bernard, C., El Helali, N., Jarlier, V., Reibel, F., Chavanet, P., Aubry, A. and Veziris, N. (2017). Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? J Antimicrob Chemother 72, 2326–2333,
Maitre, T., Aubry, A., Jarlier, V., Robert, J., Veziris, N., Bernard, C., Sougakoff, W., Brossier, F., Cambau, E., Mougari, F. and Raskine, L. (2017). Multidrug and extensively drug-resistant tuberculosis. Médecine et Maladies Infectieuses 47, 3–10,
Mazoyer, A., Ycart, B. and Veziris, N. (2017). Correction: Unbiased Estimation of Mutation Rates under Fluctuating Final Counts. PLOS ONE 12, e0173143,
Mougari, F., Loiseau, J., Veziris, N., Bernard, C., Bercot, B., Sougakoff, W., Jarlier, V., Raskine, L. and Cambau, E. (2017). Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother 72, 1669–1677,
Mougari, F., Bouziane, F., Crockett, F., Nessar, R., Chau, F., Veziris, N., Sapriel, G., Raskine, L. and Cambau, E. (2017). Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother 61, e00943-16,
Schön, T., Miotto, P., Köser, C. U., Viveiros, M., Böttger, E. and Cambau, E. (2017). Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clinical Microbiology and Infection 23, 154–160,
Veziris, N., Bernard, C., Guglielmetti, L., Du, D. L., Marigot-Outtandy, D., Jaspard, M., Caumes, E., Lerat, I., Rioux, C., Yazdanpanah, Y., Tiotiu, A., Lemaitre, N., Brossier, F., Jarlier, V., Robert, J., Sougakoff, W. and Aubry, A. (2017). Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. European Respiratory Journal 49, 1601719,
Wyplosz, B., Mougari, F., Rawi, M. A., Baillon, C., Marigot-Outtandy, D., Dû, D. L., Jachym, M., Hervé, V., Raskine, L. and Cambau, E. (2017). Visualizing viable Mycobacterium tuberculosis in sputum to monitor isolation measures. Journal of Infection 74, 207–210,

Publications du CNR en 2018

Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., Benedetti, A., Bisson, G. P., Boeree, M. J., Bonnet, M., Brode, S. K., Brust, J. C. M., Cai, Y., Caumes, E., Cegielski, J. P., Centis, R., Chan, P.-C., Chan, E. D., Chang, K.-C., Charles, M., Cirule, A., Dalcolmo, M. P., D’Ambrosio, L., de Vries, G., Dheda, K., Esmail, A., Flood, J., Fox, G. J., Fréchet-Jachym, M., Fregona, G., Gayoso, R., Gegia, M., Gler, M. T., Gu, S., Guglielmetti, L., Holtz, T. H., Hughes, J., Isaakidis, P., Jarlsberg, L., Kempker, R. R., Keshavjee, S., Khan, F. A., Kipiani, M., Koenig, S. P., Koh, W.-J., Kritski, A., Kuksa, L., Kvasnovsky, C. L., Kwak, N., Lan, Z., Lange, C., Laniado-Laborín, R., Lee, M., Leimane, V., Leung, C.-C., Leung, E. C.-C., Li, P. Z., Lowenthal, P., Maciel, E. L., Marks, S. M., Mase, S., Mbuagbaw, L., Migliori, G. B., Milanov, V., Miller, A. C., Mitnick, C. D., Modongo, C., Mohr, E., Monedero, I., Nahid, P., Ndjeka, N., O’Donnell, M. R., Padayatchi, N., Palmero, D., Pape, J. W., Podewils, L. J., Reynolds, I., Riekstina, V., Robert, J., Rodriguez, M., Seaworth, B., Seung, K. J., Schnippel, K., Shim, T. S., Singla, R., Smith, S. E., Sotgiu, G., Sukhbaatar, G., Tabarsi, P., Tiberi, S., Trajman, A., Trieu, L., Udwadia, Z. F., van der Werf, T. S., Veziris, N., Viiklepp, P., Vilbrun, S. C., Walsh, K., Westenhouse, J., Yew, W.-W., Yim, J.-J., Zetola, N. M., Zignol, M. and Menzies, D. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet 392, 821–834,
Ates, L. S., Dippenaar, A., Sayes, F., Pawlik, A., Bouchier, C., Ma, L., Warren, R. M., Sougakoff, W., Majlessi, L., van Heijst, J. W. J., Brossier, F. and Brosch, R. (2018). Unexpected Genomic and Phenotypic Diversity of Mycobacterium africanum Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity. Genome Biol Evol 10, 1858–1874,
Bastard, M., Guglielmetti, L., Huerga, H., Hayrapetyan, A., Khachatryan, N., Yegiazaryan, L., Faqirzai, J., Hovhannisyan, L., Varaine, F. and Hewison, C. (2018). Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They? Am J Respir Crit Care Med 198, 1228–1231,
Bergot, E., Abiteboul, D., Andréjak, C., Antoun, F., Barras, E., Blanc, F.-X., Bourgarit, A., Charlois-Ou, C., Delacourt, C., Dirou, S., Gerin, M., Guerin, S., Haustraete, É., Henry, B., Lucet, J.-C., Maitre, T., Morin, J., Le Palud, P., Pommelet, V., Rivoisy, C., Robert, J., Veziris, N. and Herrmann, J.-L. (2018). [Practice recommendations for the use and interpretation of interferon gamma release assays in the diagnosis of latent and active tuberculosis]. Rev Mal Respir 35, 852–858,
Blanc, F.-X., Dirou, S., Morin, J. and Veziris, N. (2018). [Interferon gamma release assay tests for the diagnosis of active tuberculosis]. Rev Mal Respir 35, 894–899,
Cambau, E. (2018). Antileprosy drugs: mode of action and mechanisms. In: International textbook of leprosy, URL: [Accessed May 2022].
Cambau, E., Saunderson, P., Matsuoka, M., Cole, S. T., Kai, M., Suffys, P., Rosa, P. S., Williams, D., Gupta, U. D., Lavania, M., Cardona-Castro, N., Miyamoto, Y., Hagge, D., Srikantam, A., Hongseng, W., Indropo, A., Vissa, V., Johnson, R. C., Cauchoix, B., Pannikar, V. K., Cooreman, E. a. W. D., Pemmaraju, V. R. R., Gillini, L., Kriswamati, A., Al-Samie, A. R., Issoufou, A., Tiendrebeogo, A., Kingalu, A., Randrianantoandro, A., Kumar, A., Chauffour, A., Win, A. A., Pandey, B., Agrawal, C. M., Widaningrum, C., Schmotzer, C., Kafando, C., Bhandari, C. M., Sema, C., Vidanagama, D. S., Scollard, D. M., Beyene, D., Morelo, E. F., Kassa, E. D., Ramarolahy, E. B., Claco, E., Villalon, E. E., Sidibe, F., Sakho, F., Abdoulaye, F., Guilengue, F. F., Gajete, F., Babu, G. R., Moussa, G., Thakur, G. D., Cabanos, G., Sock, G., Clugston, G., Zaidy, H., Watanabe, H., Kawuma, H. J., Mallari, I. B., Goulart, I. M. B., Ahamed, I., Subbanna, J., Houzeo, J. G., Luengu, J. N. M., Bertolli, J., Lloyd-Owen, J., Matheu, J., Brunelli, J. P., Alzate, J. C. B., Neupane, Kapil Dev, Osuga, K., Yamaguchi, K., Azam, K., Lin, K. M., Momoudu, K., Kyaw, K., Bide, L., Doanh, L. H., My, L. H., Shah, M., Kodio, M., Sidibe, M., Ebenezer, M., Grossi, M. A. de F., Balagon, M. F., Canlonon, M., Makino, M., Htoo, M. M., Ahmed, M. J., Nadine, M.-M., Roferos, F. O., Krismawati, H., Thida, M., Htoon, M. T., Neupane, K. D., Phuc, N. H. N., Van, N. H., Hai, N. P. N., Ishii, N., Soe, O., Amiel, O., Tossou, O., Konare, O., Joshi, P. L., Rao, P. V. R., Krishnamurthy, P., Brennan, P. J., Busso, P., Bhatia, R., Andrianarivelo, M. R., Ramdas, D. R., Chabi, R., Gusmao, R., DjupuriIzwardy, R., Soares, R. C. F. R., Jhadav, R., Buhrer, S., Cho, S.-N. R., Jianping, S., Lzumi, S., Barua, S., Chaitanya, S., Tiendrebeogo, S. M. R., Khang, T. H., Gillis, T. P., Mori, T., Vijayalakshmi, V., Kamara, V. D., Wei, W., Smith, W. C. S., Li, W., Lew, W., Al-Qubati, Y., Suzuki, Y. and Nanba, Y. (2018). Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection 24, 1305–1310,
Chauffour, A., Lecorche, E., Reibel, F., Mougari, F., Raskine, L., Aubry, A., Jarlier, V. and Cambau, E. (2018). Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. Clinical Microbiology and Infection 24, 1213.e5-1213.e8,
Coolen-Allou, N., Touron, T., Belmonte, O., Gazaille, V., Andre, M., Allyn, J., Picot, S., Payet, A. and Veziris, N. (2018). Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients. Antimicrobial Agents and Chemotherapy 62, e00395-18,
D’Ambrosio, L., Bothamley, G., Caminero Luna, J. A., Duarte, R., Guglielmetti, L., Muñoz Torrico, M., Payen, M. C., Saavedra Herrera, N., Salazar Lezama, M. A., Skrahina, A., Tadolini, M., Tiberi, S., Veziris, N. and Migliori, G. B. (2018). Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. Pulmonology 24, 132–141,
Gras, J., De Castro, N., Montlahuc, C., Champion, L., Scemla, A., Matignon, M., Lachâtre, M., Raskine, L., Grall, N., Peraldi, M. N. and Molina, J. M. (2018). Clinical characteristics, risk factors, and outcome of tuberculosis in kidney transplant recipients: A multicentric case-control study in a low-endemic area. Transplant Infectious Disease 20, e12943,
Griffith, D. E., Eagle, G., Thomson, R., Aksamit, T. R., Hasegawa, N., Morimoto, K., Addrizzo-Harris, D. J., O’Donnell, A. E., Marras, T. K., Flume, P. A., Loebinger, M. R., Morgan, L., Codecasa, L. R., Hill, A. T., Ruoss, S. J., Yim, J.-J., Ringshausen, F. C., Field, S. K., Philley, J. V., Wallace, R. J., van Ingen, J., Coulter, C., Nezamis, J. and Winthrop, K. L. (2018). Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med 198, 1559–1569,
Guglielmetti, L., Barkane, L., Dû, D. L., Marigot-Outtandy, D., Robert, J., Veziris, N., Yazdanpanah, Y., Kuksa, L., Caumes, E. and Fréchet-Jachym, M. (2018). Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. European Respiratory Journal 51, 1702550,
Guglielmetti, L., Tiberi, S., Burman, M., Kunst, H., Wejse, C., Togonidze, T., Bothamley, G. and Lange, C. (2018). QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. European Respiratory Journal 52,
Guglielmetti, L., Veziris, N., Aubry, A., Brossier, F., Bernard, C., Sougakoff, W., Jarlier, V., Robert, J. and surveillance, for the L. N. for M. (2018). Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study., doi:info:doi/10.5588/ijtld.17.0387.
Kouriba, B., Ouwe Missi Oukem-Boyer, O., Traoré, B., Touré, A., Raskine, L. and Babin, F. X. (2018). Installing biosafety level 3 containment laboratories in low- and middle-income countries: challenges and prospects from Mali’s experience. New Microbes New Infect 26, S74–S77,
Lecorche, E., Haenn, S., Mougari, F., Kumanski, S., Veziris, N., Benmansour, H., Raskine, L., Moulin, L., Cambau, E., Aubry, A., Brossier, F., Chauffour, A., Jaffre, J., Jarlier, V., Robert, J. and Sougakoff, W. (2018). Comparison of methods available for identification of Mycobacterium chimaera. Clinical Microbiology and Infection 24, 409–413,
Levi, L. I., Schlemmer, F., de Castro, N., Brun, O., Veziris, N., Argemi, X., Roupret, M., Launay, O., Bergeron, A. and Groh, M. (2018). Bacillus Calmette-Guerin infection following intravesical instillation: Does the strain matter? Médecine et Maladies Infectieuses,
Machado, D., Lecorche, E., Mougari, F., Cambau, E. and Viveiros, M. (2018). Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. Front Microbiol 9,
Maitre, T., Robert, J. and Veziris, N. (2018). Introduction: épidémiologie de la tuberculose et de l’infection tuberculeuse latente. Rev Mal Respir 35, 859–861,
Mieras, L. F., Taal, A. T., van Brakel, W. H., Cambau, E., Saunderson, P. R., Smith, W. C. S., Prakoeswa, C. R. S., Astari, L., Scollard, D. M., do Nascimento, D. C., Grosset, J., Kar, H. K., Izumi, S., Gillini, L., Virmond, M. C. L. and Sturkenboom, M. G. G. (2018). An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++. BMC Infectious Diseases 18, 506,
Rueda, D., Bernard, C., Gandy, L., Capton, E., Boudjelloul, R., Brossier, F., Veziris, N., Zimic, M. and Sougakoff, W. (2018). Estimation of pyrazinamidase activity using a cell-free In vitro synthesis of pnca and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis. Int J Mycobacteriol 7, 16–25,
Sayes, F., Blanc, C., Ates, L. S., Deboosere, N., Orgeur, M., Le Chevalier, F., Gröschel, M. I., Frigui, W., Song, O.-R., Lo-Man, R., Brossier, F., Sougakoff, W., Bottai, D., Brodin, P., Charneau, P., Brosch, R. and Majlessi, L. (2018). Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. Cell Reports 23, 1072–1084,
Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N. P., Schneide, P., Ruf, M.-T., Lamelas, A., Manimekalai, M. S. S., Grüber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G. and Pethe, K. (2018). Targeting the Mycobacterium ulcerans cytochrome bc 1 : aa 3 for the treatment of Buruli ulcer. Nature Communications 9, 5370,
van Ingen, J., Aksamit, T., Andrejak, C., Böttger, E. C., Cambau, E., Daley, C. L., Griffith, D. E., Guglielmetti, L., Holland, S. M., Huitt, G. A., Koh, W.-J., Lange, C., Leitman, P., Marras, T. K., Morimoto, K., Olivier, K. N., Santin, M., Stout, J. E., Thomson, R., Tortoli, E., Wallace, R. J., Winthrop, K. L. and Wagner, D. (2018). Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal 51, 1800170,
Walker, T. M., Merker, M., Knoblauch, A. M., Helbling, P., Schoch, O. D., Werf, M. J. van der, Kranzer, K., Fiebig, L., Kröger, S., Haas, W., Hoffmann, H., Indra, A., Egli, A., Cirillo, D. M., Robert, J., Rogers, T. R., Groenheit, R., Mengshoel, A. T., Mathys, V., Haanperä, M., Soolingen, D. van, Niemann, S., Böttger, E. C., Keller, P. M., Avsar, K., Bauer, C., Bernasconi, E., Borroni, E., Brusin, S., Dévis, M. C., Crook, D. W., Dedicoat, M., Fitzgibbon, M., Gagneux, S., Geiger, F., Guthmann, J.-P., Hendrickx, D., Hoffmann-Thiel, S., Ingen, J. van, Jackson, S., Jaton, K., Lange, C., Stalder, J. M., O’Donnell, J., Opota, O., Peto, T. E. A., Preiswerk, B., Roycroft, E., Sato, M., Schacher, R., Schulthess, B., Smith, E. G., Soini, H., Sougakoff, W., Tagliani, E., Utpatel, C., Veziris, N., Wagner-Wiening, C. and Witschi, M. (2018). A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. The Lancet Infectious Diseases 18, 431–440,
World Health Organization (2018). Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis, WHO, Geneva, URL:

Publications du CNR en 2019

Andrés, M., Werf, M. J. van der, Ködmön, C., Albrecht, S., Haas, W., Fiebig, L. and Group, S. study (2019). Molecular and genomic typing for tuberculosis surveillance: A survey study in 26 European countries. PLOS ONE 14, e0210080,
Aubry, A. and Veziris, N. (2019). Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections. Am J Respir Crit Care Med 200, 1072–1073,
Baron, V., Forfait, C., Colot, J., Carzola, C., Descloux, E., Cauchoix, B., Cambau, E., Gaumery, J., Grangeon, J. and Klement, E. (2019). Épidémiologie de la lèpre en Nouvelle-Calédonie de 1983 à 2017. BEH 400–405, URL: [Accessed February 2022].
Bouziane, F., Allem, R., Sebaihia, M., Kumanski, S., Mougari, F., Sougakoff, W., Raskine, L., Yala, D. and Cambau, E. (2019). First genetic characterisation of multidrug-resistant Mycobacterium tuberculosis isolates from Algeria. Journal of Global Antimicrobial Resistance 19, 301–307,
Daniau, C., Lecorché, E., Mougari, F. and et al. (2019). Infections invasives à Mycobacterium chimaera en chirurgie cardiaque et évaluation des pratiques autour des matériels de circulation extracorporelle. Hygienes 27, 351–359,
Decalonne, M., Lecorche, E., Hau, E., Petiteau, A., Moreau, C., Milan, O., Lanotte, P., Mereghetti, L., Cambau, E. and van der Mee-Marquet, N. (2019). Cause Analysis of an Infection in Facelift Surgery Due to Mycobacterium chelonae. Frontiers in Medicine 6, URL: [Accessed February 2022].
Dutertre, M., Delobel, P., Marchou, B., Boyer, J.-F., Mougari, F. and Martin-Blondel, G. (2019). Olecranon bursitis secondary to Mycobacterium europaeum infection in a patient receiving immunosuppressive drugs for rheumatoid arthritis. Médecine et Maladies Infectieuses 49, 358–359,
Guglielmetti, L., Jaffré, J., Bernard, C., Brossier, F., El Helali, N., Chadelat, K., Thouvenin, G., Dautzenberg, B., Henry, B., Jaspard, M., Guillot, H., Pourcher, V., Le Dû, D., Marigot-Outtandy, D., Mougari, F., Raskine, L., Rivoire, B., Andrejak, C., Jarlier, V., Aubry, A., Robert, J., Frechet-Jachym, M. and Veziris, N. (2019). Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. The International Journal of Tuberculosis and Lung Disease 23, 1050–1054,
Guglielmetti, L., Sougakoff, W., Maitre, T., Brossier, F., Jarlier, V., Robert, J., Veziris, N. and Aubry, A. (2019). Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. Clinical Infectious Diseases 68, 1410–1411,
Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., Fréchet-Jachym, M., Robert, J., Veziris, N., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., Schünemann, H. J. and Lienhardt, C. (2019). Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis 25,
Perrineau, S., Lachâtre, M., Lê, M. P., Rioux, C., Loubet, P., Fréchet-Jachym, M., Gonzales, M. C., Grall, N., Bouvet, E., Veziris, N., Yazdanpanah, Y. and Peytavin, G. (2019). Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 23, 99–104,
Petrella, S., Capton, E., Raynal, B., Giffard, C., Thureau, A., Bonneté, F., Alzari, P. M., Aubry, A. and Mayer, C. (2019). Overall Structures of Mycobacterium tuberculosis DNA Gyrase Reveal the Role of a Corynebacteriales GyrB-Specific Insert in ATPase Activity. Structure 27, 579-589.e5,
Rodriguez, C. A., Brooks, M. B., Guglielmetti, L., Hewison, C., Jachym, M. F., Lessem, E., Varaine, F. and Mitnick, C. D. (2019). Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action 9, 32–41,
Rollet-Cohen, V., Roux, A.-L., Bourgeois, M. L., Sapriel, G., Bahri, M. E., Jais, J.-P., Heym, B., Mougari, F., Raskine, L., Véziris, N., Gaillard, J.-L. and Sermet-Gaudelus, I. (2019). Mycobacterium bolletii lung disease in cystic fibrosis. CHEST 0,
Sane Schepisi, M., Navarra, A., Altet Gomez, M. N., Dudnyk, A., Dyrhol-Riise, A. M., Esteban, J., Giorgetti, P. F., Gualano, G., Guglielmetti, L., Heyckendorf, J., Kaluzhenina, A., Lange, B., Lange, C., Manika, K., Miah, J., Nanovic, Z., Pontali, E., Prego, M. R., Solovic, I., Tiberi, S., Palmieri, F. and Girardi, E. (2019). Burden and Characteristics of the Comorbidity Tuberculosis—Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. Open Forum Infectious Diseases 6, ofy337,
van Leth, F., Brinkmann, F., Cirillo, D. M., Dheda, K., Duarte, R., Guglielmetti, L., Kuksa, L., Lange, C., Mitnick, C., Skrahina, A., Zaman, K. and Bothamley, G. (2019). The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal 53,